добавлена новая статья Health

2026-02-13 06:39:31 - Перевод

The "Gut-Liver Axis" Strategy: Is 2026 the Year We Treat the Intestine to Save the Liver?

A major shift in the 2026 global industry is the record-breaking focus on "PSC-IBD Combined Care." Because nearly 80% of PSC patients also suffer from Inflammatory Bowel Disease (IBD), the Primary Sclerosing Cholangitis Market has launched several trials for dual-action therapies. This year, research into COL7A1 and ABCB9 proteins has identified them as shared genetic targets for both...

0 Комментарии 0 Поделились 15 Просмотры 0 предпросмотр